https://www.selleckchem.com/products/abt-199.html
2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for ≥ 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL. © Indian Society of Hematology and Blood Transfusion 2019.Low-grade Nonhodgkin lymphoma (LG-NHL) is characterized by indolent clinical course, which cons
Like
Comment
Share
